Updated results from the phase 3 XTEND-1 trial were presented at ISTH, once again comparing the therapy to patients' previous treatment with clotting factor replacement.

In addition to their ability to directly inflict damage on macromolecules, ROS and RNS indirectly induce damage to tissues by activating a number of cellular stress-sensitive pathways. These ...

Small Animal Hospital, University of Glasgow, Glasgow G61 1QH, Scotland, U.K.